Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.34 |
| ▸ | F10 | P00742 | 4/20 | 0.32 |
| ▸ | F2 | P00734 | 2/20 | 0.32 |
| ▸ | F9 | P00740 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338940 | 0.87 | F10 (0.41) | DPP4DPP8DPP9F10F2 | |
| SCHEMBL339964 | 0.81 | DPP4 (0.41) | DPP4DPP8DPP9CNR1MEN1 | |
| SCHEMBL338672 | 0.81 | DPP4 (0.49) | DPP4DPP8DPP9PIK3CAMEN1 | |
| SCHEMBL339904 | 0.81 | ALPL (0.46) | DPP4DPP8DPP9MEN1KMT2A | |
| SCHEMBL339827 | 0.81 | DPP4 (0.43) | DPP4DPP8DPP9CNR1MEN1 | |
| SCHEMBL339770 | 0.81 | PIK3CA (0.44) | DPP4DPP8DPP9CNR1PIK3CA | |
| SCHEMBL1911458 | 0.80 | DPP4 (0.41) | DPP4DPP8DPP9CNR1MEN1 | |
| SCHEMBL340135 | 0.79 | DPP4 (0.42) | DPP4DPP8DPP9CNR1CNR2 | |
| SCHEMBL340178 | 0.79 | DPP4 (0.42) | DPP4DPP8DPP9CNR1PIK3CA | |
| SCHEMBL340329 | 0.78 | KDM4E (0.45) | DPP4DPP8MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253689-A1 | Organic Compounds | OAT, GPR119, OTC | DPP4 120/4885DPP8 403/4885DPP9 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.